Oxford BioMedica (LSE:OXB) FCF Margin % : -60.42% (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Oxford BioMedica's Free Cash Flow for the six months ended in Dec. 2023 was £-28.08 Mil. Oxford BioMedica's Revenue for the six months ended in Dec. 2023 was £46.48 Mil. Therefore, Oxford BioMedica's FCF Margin % for the quarter that ended in Dec. 2023 was -60.42%.

As of today, Oxford BioMedica's current FCF Yield % is -11.73%.

The historical rank and industry rank for Oxford BioMedica's FCF Margin % or its related term are showing as below:

LSE:OXB' s FCF Margin % Range Over the Past 10 Years
Min: -187.53 Med: -25.28 Max: 11.2
Current: -42.83

During the past 13 years, the highest FCF Margin % of Oxford BioMedica was 11.20%. The lowest was -187.53%. And the median was -25.28%.

LSE:OXB's FCF Margin % is ranked better than
63% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs LSE:OXB: -42.83

Oxford BioMedica FCF Margin % Historical Data

The historical data trend for Oxford BioMedica's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica FCF Margin % Chart

Oxford BioMedica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-45.71

-11.67

11.20

-20.65

-42.83

Oxford BioMedica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-4.32	-47.67	2.12	-23.85	-60.42

Competitive Comparison of Oxford BioMedica's FCF Margin %

For the Biotechnology subindustry, Oxford BioMedica's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioMedica's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's FCF Margin % falls into.

Oxford BioMedica FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Oxford BioMedica's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-38.349	/	89.539
	=	-42.83 %

Oxford BioMedica's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-28.081	/	46.478
	=	-60.42 %

Oxford BioMedica FCF Margin % Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oxford BioMedica (LSE:OXB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

OXBDF:USA OXBl:UK OXO:Germany

Address

Windrush Court, Transport Way, Oxford, GBR, OX4 6LT

Website

https://www.oxb.com

Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines